Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

NCT00569946 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer